Geovax, Inc. (GOVX), a biotechnology company developing innovative human vaccines using its novel DNA/MVA platform technology, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D., gave an oral presentation entitled Elicitation of Immune Responses by a DNA/MVA Vaccine in ART Treated Patients in a Treatment Interruption Trial. Dr. Robinson delivered the presentation at the #HIV Research for Prevention 2014: #AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P) conference in Cape Town, South Africa.
Posted on: Thu, 30 Oct 2014 14:22:52 +0000